N-ACETYL CYSTEINE IN SCHIZOPHRENIA RESISTANT TO CLOZAPINE: A DOUBLE-BLIND RANDOMISED PLACEBO-CONTROLLED TRIAL TARGETING NEGATIVE SYMPTOMS
Grant number: 1098442 | Funding period: 2016 - 2019
Completed
Abstract
Many patients with schizophrenia remain treatment resistant even after “last resort” medications like clozapine. This proposal will conduct a novel multi-site randomised placebo controlled trial of adjunctive N-acetyl cysteine in patients with clozapine resistant schizophrenia. Treatment efficacy will be examined at 8, 26 and 52 weeks.